Primary Lateral Sclerosis Treatments
Find Primary Lateral Sclerosis Treatments
Medications for Primary Lateral Sclerosis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Primary Lateral Sclerosis.
Found 4 Approved Drugs for Primary Lateral Sclerosis
Spinraza
Generic Name
Nusinersen
Spinraza
Generic Name
Nusinersen
Form: Injection
Method of administration: Intrathecal
FDA approval date: December 23, 2016
Classification: Antisense Oligonucleotide
SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients ( 1 )
Radicava
Generic Name
Edaravone
Radicava
Generic Name
Edaravone
Form: Injection, Kit
Method of administration: Intravenous
FDA approval date: May 12, 2022
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )
Qalsody
Generic Name
Tofersen
Qalsody
Generic Name
Tofersen
Form: Injection
Method of administration: Intrathecal
FDA approval date: April 25, 2023
Classification: Antisense Oligonucleotide
QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). QALSODY is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). ( 1 )
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances